[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Investor Gadget 🕵️♂️🧬📈 [@ilzizzo](/creator/twitter/ilzizzo) on x 1731 followers Created: 2025-07-17 05:36:46 UTC $RARE remains a moderate risk, high-reward investment. The Orbit study’s adherence to its 18-month timeline and their clean FDA approval record (4-for-4, no CRLs) strengthen its long-term potential in the rare disease space. UX111’s delay is a manageable hurdle anticipated approval in 2026 - They have roughly $550mm in cash with $414mm burn and projected to do $650mm in revenue this year. Cash burn and potential dilution risk warrant caution. For risk-tolerant investors with a 24+ month horizon, with a target of $65–$85 by end-2026 if pipeline milestones are met. A “Hold” or “Watch” stance is prudent for now, awaiting clarity on financing (Q4 2025) or key readouts (e.g., Orbit final analysis, Angelman syndrome enrollment). Keep in mind biotech wasteland looks cheap but is looking like another 2-5 year horizon. “If you waste time watering a fruitless tree, fruitful ones may die of thirst.” MATSHONA DHLIWAYO XXX engagements  **Related Topics** [$650mm](/topic/$650mm) [$414mm](/topic/$414mm) [$550mm](/topic/$550mm) [longterm](/topic/longterm) [$rare](/topic/$rare) [investment](/topic/investment) [superrare](/topic/superrare) [superrarebears](/topic/superrarebears) [Post Link](https://x.com/ilzizzo/status/1945719305892659570)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Investor Gadget 🕵️♂️🧬📈 @ilzizzo on x 1731 followers
Created: 2025-07-17 05:36:46 UTC
$RARE remains a moderate risk, high-reward investment. The Orbit study’s adherence to its 18-month timeline and their clean FDA approval record (4-for-4, no CRLs) strengthen its long-term potential in the rare disease space.
UX111’s delay is a manageable hurdle anticipated approval in 2026 - They have roughly $550mm in cash with $414mm burn and projected to do $650mm in revenue this year.
Cash burn and potential dilution risk warrant caution. For risk-tolerant investors with a 24+ month horizon, with a target of $65–$85 by end-2026 if pipeline milestones are met. A “Hold” or “Watch” stance is prudent for now, awaiting clarity on financing (Q4 2025) or key readouts (e.g., Orbit final analysis, Angelman syndrome enrollment).
Keep in mind biotech wasteland looks cheap but is looking like another 2-5 year horizon.
“If you waste time watering a fruitless tree, fruitful ones may die of thirst.” MATSHONA DHLIWAYO
XXX engagements
Related Topics $650mm $414mm $550mm longterm $rare investment superrare superrarebears